

# The benefit of a dermocosmetic in telogen effluvium

Donato Di Nunno<sup>1</sup>, Alfredo Rossi<sup>2</sup>, Daniele Campo<sup>3</sup>, Victor Desmond Mandel<sup>4</sup>, Pinaki Bhattacharya<sup>5</sup>, Beatriz Sant'Anna<sup>5</sup>, Stéphanie Leclerc-Mercier<sup>5</sup>

<sup>1</sup>Department of Medicine, Dermatology and STDs Unit, "Celio" Military Polyclinic of Rome, Rome, Italy, <sup>2</sup>Dermatologic Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, <sup>3</sup>Istituto Ortodermico Italiano, Rome, Italy, <sup>4</sup>Porphyria and Rare Diseases Unit, San Gallicano Dermatological Institute – IRCCS, Rome, Italy, <sup>5</sup>Vichy Laboratoires, Levallois-Perret, France

## 1 INTRODUCTION

Telogen effluvium (TE) is one of the most common causes of alopecia. It is characterized by excessive shedding of hair. Several factors such as drugs, trauma, and emotional and physiological stress can lead to the development of chronic TE. Multiple alterations in the hair cycle have been proposed as the underlying mechanism. Telogen effluvium can present as acute or chronic hair fall with symptoms such as trichodynia.<sup>1,2</sup> A limited benefit of topical or systemic anti-hair loss treatment along with medical treatments has been reported in the literature in chronic TE.<sup>3-5</sup>

The dermocosmetic AMI5 contains 2,4 diamino-pyrimidine-oxide, SP94, Arginine, Piroctone Olamine, Vichy thermal water and was developed to manage specifically hair loss.

## 2 OBJECTIVE

To assess the efficacy of AMI5 on the diameter of the hair shaft and hair density, its local tolerance and subject satisfaction in patients with chronic TE.


## 3 MATERIALS & METHODS

- This was an open-label, multicenter, prospective observational study
- 20 subjects with chronic TE, with no treatment for their hair loss, applied AMI5 on their scalp and hair every day during 3 months followed by 3 times a week during the following 9 months
- The average diameter of hair shaft and hair density were measured using Trichoscan at baseline, Month 3, 6 and 12
- Tolerability and satisfaction regarding the subject-perceived improvement in the hair condition were assessed at baseline and after 12 months

## 4 RESULTS


- A significant ( $p < 0.001$ ) increase of 9.0% in hair diameter (Figure 1) and 22.0% in hair density (Figure 2) was observed at the end of the study compared to baseline
- Chronic TE had significantly ( $p < 0.001$ ) improved in all subjects after 12 months of AMI5 use
- Figure 3 provides visual results of chronic TE improvement from 2 subjects after 12 months of use
- Figure 4 provides results from Trichoscopy at baseline and after 12 months
- Subjects highly appreciated AMI5
- AMI5 was well tolerated

**FIGURE 1: Evolution over time of Hair thickness**




The increase was significant ( $p < 0.001$ ) from baseline as early as Month 3

**FIGURE 2: Evolution over time of Hair density**



The increase was significant ( $p < 0.001$ ) from baseline as early as Month 3

**FIGURE 3: Evolution over time of Hair density**



**FIGURE 4: Trichoscopy: Results at baseline and after 12 Months**



## 5 CONCLUSIONS

- AMI5 is beneficial in increasing hair density and thickness in subjects with chronic TE.
- Subjects highly appreciated and well tolerated AC5.
- AMI5 may be considered an option to manage chronic TE.

**References:** 1. Asghar F, Shamim N, Faraouq U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. *Cureus*. 2020;12(5):e8320. 2. Rebara A. Telogen effluvium: a comprehensive review. *Clinical, cosmetic and investigational dermatology*. 2019;12:583-90. 3. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. *J Am Acad Dermatol*. 2021;84(3):737-46. 4. Khattab FM, Rady A, Khashaba SA. Recent modalities in treatment of telogen effluvium: Comparative study. *Dermatologic therapy*. 2022;35(10):e15720. 5. Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. *J Drugs Dermatol*. 2018;17(4):457-63.

**Acknowledgments:** The authors acknowledge the writing support of Karl Patrick Göritz, SMWS, France and the art work of Dominique Poisson.

**Key words:** Telogen effluvium, dermocosmetic, hair density, hair thickness.